Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenoviridae Infections × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 409 Melanoma 268 Squamous Cell Carcinoma of Head and Neck 203 Parkinson Disease 4, Autosomal Dominant Lewy Body 165 Neoplasms 160 Breast Neoplasms 146 Triple Negative Breast Neoplasms 142 Neoplasm Metastasis 135 Lung Neoplasms 132 Colorectal Neoplasms 129 Carcinoma, Renal Cell 116 Head and Neck Neoplasms 106 Ovarian Neoplasms 94 Stomach Neoplasms 91 Carcinoma, Transitional Cell 76 Pancreatic Neoplasms 73 Urinary Bladder Neoplasms 71 Carcinoma, Hepatocellular 66 Endometrial Neoplasms 62 Uterine Cervical Neoplasms 57 Esophageal Neoplasms 53 Recurrence 46 Prostatic Neoplasms 45 Carcinoma 39 Glioblastoma 38 Sarcoma 36 Carcinoma, Squamous Cell 36 Small Cell Lung Carcinoma 32 Lymphoma 32 Fallopian Tube Neoplasms 32

Interventions

Gemcitabine 2 Cell Count 2 ziprasidone 1 valrubicin 1 tretazicar 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 enadenotucirev 1 atezolizumab 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Vaccines 1 Tumor Necrosis Factor-alpha 1 Tranexamic Acid 1 Tobramycin 1 Spironolactone 1 Sevelamer 1 Rocuronium 1 Radiotherapy 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Oncolytic Virotherapy 1 Nifedipine 1 Nafcillin 1 Molindone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271318 2025-11-03

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡